<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407030</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 60201-0408</org_study_id>
    <nct_id>NCT00407030</nct_id>
  </id_info>
  <brief_title>IncobotulinumtoxinA (Xeomin) Versus Placebo in the Treatment of Cervical Dystonia</brief_title>
  <official_title>Prospective, Double-blind, Placebo-controlled, Randomized, Multi-center Trial With a Double-blind Parallel-group Extension Period to Investigate the Efficacy and Safety of Different Doses of IncobotulinumtoxinA (Xeomin) in the Treatment of Cervical Dystonia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      At baseline patients received incobotulinumtoxinA (Xeomin) or placebo. Thereafter, all
      patients who entered the extension period were treated with up to five injection sessions of
      incobotulinumtoxinA (Xeomin) during the extension period.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2006</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">January 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Placebo</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (120 Units) Versus Placebo</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Xeomin (120 Units)</measure>
    <time_frame>Baseline, week 4</time_frame>
    <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the TWSTRS-Total Score</measure>
    <time_frame>Baseline, week 8, final visit (up to 20 weeks after injection of the Main Period)</time_frame>
    <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the TWSTRS Disability Subscore</measure>
    <time_frame>Baseline, week 4, week 8, final visit (up to 20 weeks after injection of the Main Period)</time_frame>
    <description>TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the TWSTRS Severity Subscore</measure>
    <time_frame>Baseline, week 4, week 8, final visit (up to 20 weeks after injection of the Main Period)</time_frame>
    <description>TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in the TWSTRS Pain Subscore</measure>
    <time_frame>Baseline, week 4, week 8, final visit (up to 20 weeks after injection of the Main Period)</time_frame>
    <description>TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Evaluation of Global Response (PEGR) at Final Visit</measure>
    <time_frame>Final visit (up to 20 weeks after injection of the Main Period)</time_frame>
    <description>The PEGR is a descriptive subjective 9-point response scale ranging from &quot;complete abolishment of signs and symptoms&quot; (value=+4) down to &quot;very marked worsening&quot; (value=-4).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Cervical Dystonia</condition>
  <arm_group>
    <arm_group_label>incobotulinumtoxinA (Xeomin) (240 Units)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 240 units, total volume 4.8mL; Mode of administration: intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>incobotulinumtoxinA (Xeomin) (120 Units)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 120 units, total volume 4.8 mL; Mode of administration: intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 4.8 mL; Mode of administration: intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>incobotulinumtoxinA (Xeomin) (240 Units)</intervention_name>
    <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (240 Units)</description>
    <arm_group_label>incobotulinumtoxinA (Xeomin) (240 Units)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>incobotulinumtoxinA (Xeomin) (120 Units)</intervention_name>
    <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kiloDalton), free from complexing proteins&quot;) (120 Units)</description>
    <arm_group_label>incobotulinumtoxinA (Xeomin) (120 Units)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Main Inclusion Criteria:

          -  Male or female outpatients between ages 18 and 75 years inclusive)

          -  A clinical diagnosis of cervical dystonia (i.e. spasmodic torticollis) with
             predominantly rotational form and a need for injection (determined by the Toronto
             Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total score)

          -  TWSTRS-Total score &gt;= 20

          -  TWSTRS-Severity score &gt;= 10

          -  TWSTRS-Disability score &gt;= 3

          -  TWSTRS-Pain score &gt;= 1

          -  On a stable dose of medications (if any) used for focal dystonia treatment (e.g.
             anticholinergics and benzodiazepines) for at least 3 months prior to and expected
             throughout the Main Period

          -  For pre-treated patients only: Source documentation of the last two consecutive
             injection sessions with Botulinum Toxin and stable therapeutic response directly prior
             to trial entry

          -  For pre-treated patients only: At least 10 weeks must have been passed between the
             last injection with Botulinum Toxin for cervical dystonia and baseline

          -  For pre-treated patients only: The most recent injection with Botulinum Toxin must
             have been maximal 300 Units of type A or 12,000 Units of type B

        Main Exclusion Criteria:

          -  Traumatic torticollis or tardive torticollis

          -  TWSTRS-Severity score for anterocollis &gt;= 2 points (pure anterocollis)

          -  TWSTRS-Severity score for retrocollis &gt;= 2 points (pure retrocollis)

          -  Myotomy or denervation surgery in the affected muscles (e.g. peripheral denervation
             and/or spinal cord stimulation)

          -  Hypersensitivity to human serum albumin, sucrose, or Botulinum Toxin Type A

          -  Diagnosis of myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis,
             or any other significant neuromuscular disease which might interfere with the trial

          -  Current swallowing disorder of any origin (dysphagia scale &gt;= 3, i.e. severe, with
             swallowing difficulties and requiring a change in diet)

          -  Marked limitation on passive range of motion that suggests contractures or other
             structural abnormality, e.g. cervical contractures or cervical spine syndrome

          -  Treatment with Botulinum Toxins for any indication other than cervical dystonia within
             4 months prior to baseline and during the trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cynthia Comella, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Rush University Medical Center, 1725 West Harrison Street, Suite 755, Chicago, 60612 Illinois, USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Comella CL, Jankovic J, Truong DD, Hanschmann A, Grafe S; U.S. XEOMIN Cervical Dystonia Study Group. Efficacy and safety of incobotulinumtoxinA (NT 201, XEOMIN®, botulinum neurotoxin type A, without accessory proteins) in patients with cervical dystonia. J Neurol Sci. 2011 Sep 15;308(1-2):103-9. doi: 10.1016/j.jns.2011.05.041. Epub 2011 Jul 18.</citation>
    <PMID>21764407</PMID>
  </results_reference>
  <results_reference>
    <citation>Evidente VG, Fernandez HH, LeDoux MS, Brashear A, Grafe S, Hanschmann A, Comella CL. A randomized, double-blind study of repeated incobotulinumtoxinA (Xeomin(®)) in cervical dystonia. J Neural Transm (Vienna). 2013 Dec;120(12):1699-707. doi: 10.1007/s00702-013-1048-3. Epub 2013 Jun 19.</citation>
    <PMID>23779062</PMID>
  </results_reference>
  <verification_date>July 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 30, 2006</study_first_submitted>
  <study_first_submitted_qc>November 30, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <results_first_submitted>August 31, 2010</results_first_submitted>
  <results_first_submitted_qc>December 1, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2010</results_first_posted>
  <last_update_submitted>July 12, 2013</last_update_submitted>
  <last_update_submitted_qc>July 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dystonia</mesh_term>
    <mesh_term>Dystonic Disorders</mesh_term>
    <mesh_term>Torticollis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
          <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="P2">
          <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
          <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Period - 8 to 20 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="81"/>
                <participants group_id="P2" count="78"/>
                <participants group_id="P3" count="74"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="76"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="68"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal Criteria Occurred</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Extension Period - up to 68 Weeks</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="111">2 subjects did not enter the Ext. Period, 3 subjects never expressed any need for a new injection</participants>
                <participants group_id="P2" count="103">2 subjects did not enter the Ext. Period, 3 subjects never expressed any need for a new injection</participants>
                <participants group_id="P3" count="0">After the Main Period all patients were randomly assigned to the 2 active treatment arms.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="84"/>
                <participants group_id="P2" count="74"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal Criteria Occurred</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Consent Withdrawn</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
          <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="B2">
          <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
          <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="81"/>
            <count group_id="B2" value="78"/>
            <count group_id="B3" value="74"/>
            <count group_id="B4" value="233"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="12.2"/>
                    <measurement group_id="B2" value="52.8" spread="11.5"/>
                    <measurement group_id="B3" value="52.4" spread="10.8"/>
                    <measurement group_id="B4" value="52.8" spread="11.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="49"/>
                    <measurement group_id="B4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="27"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Placebo</title>
        <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Intention to treat population: all participants randomized were included in the primary efficacy analysis; missing values were imputed using the worst case strategy, i.e. imputation by baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Placebo</title>
          <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>Intention to treat population: all participants randomized were included in the primary efficacy analysis; missing values were imputed using the worst case strategy, i.e. imputation by baseline value</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="2.18"/>
                    <measurement group_id="O2" value="1.6" spread="2.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing: Primary null hypothesis: incobotulinumtoxinA (Xeomin) (240 Units) identical to placebo. Rejection of 1st hypothesis lead to test of 2nd null hypothesis: incobotulinumtoxinA (Xeomin) (120 Units) identical to placebo. Rejection of 2nd hypothesis lead to test of 3rd null hypothesis: incobotulinumtoxinA (Xeomin) (240 Units) identical to incobotulinumtoxinA (Xeomin) (120 Units). 3 separate models were used to test these hypotheses which results in different LS means estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Due to the hierarchical testing no adjustment of type I error was necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Independent variables in the model were treatment, baseline TWSTRS-Total score, gender, age, pre-treatment of cervical dystonia, and pooled center.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-9.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-12.0</ci_lower_limit>
            <ci_upper_limit>-5.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the TWSTRS-Total Score</title>
        <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, week 8, final visit (up to 20 weeks after injection of the Main Period)</time_frame>
        <population>Intention to treat population with missing values imputed using the worst case strategy, i.e. imputation by baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the TWSTRS-Total Score</title>
          <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>Intention to treat population with missing values imputed using the worst case strategy, i.e. imputation by baseline value</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.2" spread="10.54"/>
                    <measurement group_id="O2" value="-6.9" spread="11.15"/>
                    <measurement group_id="O3" value="0.4" spread="7.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.6" spread="7.52"/>
                    <measurement group_id="O2" value="-3.6" spread="8.07"/>
                    <measurement group_id="O3" value="1.7" spread="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the TWSTRS Disability Subscore</title>
        <description>TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, week 4, week 8, final visit (up to 20 weeks after injection of the Main Period)</time_frame>
        <population>Intention to treat population with missing values imputed using the worst case strategy, i.e. imputation by baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the TWSTRS Disability Subscore</title>
          <description>TWSTRS-Disability score which ranges from 0 (=no disability)to 30 (=maximum disability). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>Intention to treat population with missing values imputed using the worst case strategy, i.e. imputation by baseline value</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.0" spread="4.35"/>
                    <measurement group_id="O2" value="-3.3" spread="4.72"/>
                    <measurement group_id="O3" value="0.0" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="3.98"/>
                    <measurement group_id="O2" value="-2.1" spread="4.86"/>
                    <measurement group_id="O3" value="0.8" spread="3.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.13"/>
                    <measurement group_id="O2" value="-1.4" spread="3.82"/>
                    <measurement group_id="O3" value="1.0" spread="3.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the TWSTRS Severity Subscore</title>
        <description>TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, week 4, week 8, final visit (up to 20 weeks after injection of the Main Period)</time_frame>
        <population>Intention to treat population with missing values imputed using the worst case strategy, i.e. imputation by baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the TWSTRS Severity Subscore</title>
          <description>TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>Intention to treat population with missing values imputed using the worst case strategy, i.e. imputation by baseline value</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="5.99"/>
                    <measurement group_id="O2" value="-3.9" spread="4.34"/>
                    <measurement group_id="O3" value="-1.9" spread="3.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.5" spread="5.39"/>
                    <measurement group_id="O2" value="-3.1" spread="4.39"/>
                    <measurement group_id="O3" value="-0.9" spread="3.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="3.83"/>
                    <measurement group_id="O2" value="-1.1" spread="3.18"/>
                    <measurement group_id="O3" value="-0.2" spread="3.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in the TWSTRS Pain Subscore</title>
        <description>TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, week 4, week 8, final visit (up to 20 weeks after injection of the Main Period)</time_frame>
        <population>Intention to treat population with missing values imputed using the worst case strategy, i.e. imputation by baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the TWSTRS Pain Subscore</title>
          <description>TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>Intention to treat population with missing values imputed using the worst case strategy, i.e. imputation by baseline value</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline - Week 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="4.36"/>
                    <measurement group_id="O2" value="-2.7" spread="4.55"/>
                    <measurement group_id="O3" value="-0.3" spread="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.3" spread="4.32"/>
                    <measurement group_id="O2" value="-1.8" spread="4.15"/>
                    <measurement group_id="O3" value="0.6" spread="2.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Baseline - Final Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="3.40"/>
                    <measurement group_id="O2" value="-1.1" spread="3.96"/>
                    <measurement group_id="O3" value="0.9" spread="2.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Evaluation of Global Response (PEGR) at Final Visit</title>
        <description>The PEGR is a descriptive subjective 9-point response scale ranging from &quot;complete abolishment of signs and symptoms&quot; (value=+4) down to &quot;very marked worsening&quot; (value=-4).</description>
        <time_frame>Final visit (up to 20 weeks after injection of the Main Period)</time_frame>
        <population>Intention to treat population with missing values imputed by &quot;no effect&quot;</population>
        <group_list>
          <group group_id="O1">
            <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Evaluation of Global Response (PEGR) at Final Visit</title>
          <description>The PEGR is a descriptive subjective 9-point response scale ranging from &quot;complete abolishment of signs and symptoms&quot; (value=+4) down to &quot;very marked worsening&quot; (value=-4).</description>
          <population>Intention to treat population with missing values imputed by &quot;no effect&quot;</population>
          <units>points on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
                <count group_id="O3" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="1.84"/>
                    <measurement group_id="O2" value="1.3" spread="1.77"/>
                    <measurement group_id="O3" value="-0.2" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (120 Units) Versus Placebo</title>
        <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Intention to treat population: all participants randomized were included in the primary efficacy analysis; missing values were imputed using the worst case strategy, i.e. imputation by baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (120 Units) Versus Placebo</title>
          <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>Intention to treat population: all participants randomized were included in the primary efficacy analysis; missing values were imputed using the worst case strategy, i.e. imputation by baseline value</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="78"/>
                <count group_id="O2" value="74"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.8" spread="2.11"/>
                    <measurement group_id="O2" value="-3.3" spread="2.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing: Primary null hypothesis: incobotulinumtoxinA (Xeomin) (240 Units) identical to placebo. Rejection of 1st hypothesis lead to test of 2nd null hypothesis: incobotulinumtoxinA (Xeomin) (120 Units) identical to placebo. Rejection of 2nd hypothesis lead to test of 3rd null hypothesis: incobotulinumtoxinA (Xeomin) (240 Units) identical to incobotulinumtoxinA (Xeomin) (120 Units). 3 separate models were used to test these hypotheses which results in different LS means estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>Due to the hierarchical testing no adjustment of type I error was necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Independent variables in the model were treatment, baseline TWSTRS-Total score, gender, age, pre-treatment of cervical dystonia, and pooled center.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-7.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.4</ci_lower_limit>
            <ci_upper_limit>-4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Xeomin (120 Units)</title>
        <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
        <time_frame>Baseline, week 4</time_frame>
        <population>Intention to treat population: all participants randomized were included in the primary efficacy analysis; missing values were imputed using the worst case strategy, i.e. imputation by baseline value</population>
        <group_list>
          <group group_id="O1">
            <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
          </group>
          <group group_id="O2">
            <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
            <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) -Total Score at Week 4 After Injection of the Main Period - Xeomin (240 Units) Versus Xeomin (120 Units)</title>
          <description>The TWSTRS-Total score is the sum of scores of the three components of the scale:
TWSTRS-Severity score which ranges from 0 (=absence of severity) to 35 points (=maximum severity)
TWSTRS-Pain score which ranges from 0 (=no pain) to 20 (=maximum pain)
TWSTRS-Disability score which ranges from 0 (=no disability) to 30 (=maximum disability).
The TWSTRS total score ranges from 0 (=best value) to 85 (=worst value). The change from baseline was calculated as the score at the corresponding visit minus the baseline score.</description>
          <population>Intention to treat population: all participants randomized were included in the primary efficacy analysis; missing values were imputed using the worst case strategy, i.e. imputation by baseline value</population>
          <units>points on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="81"/>
                <count group_id="O2" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="2.25"/>
                    <measurement group_id="O2" value="-9.2" spread="2.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Hierarchical testing: Primary null hypothesis: incobotulinumtoxinA (Xeomin) (240 Units) identical to placebo. Rejection of 1st hypothesis lead to test of 2nd null hypothesis: incobotulinumtoxinA (Xeomin) (120 Units) identical to placebo. Rejection of 2nd hypothesis lead to test of 3rd null hypothesis: incobotulinumtoxinA (Xeomin) (240 Units) identical to incobotulinumtoxinA (Xeomin) (120 Units). 3 separate models were used to test these hypotheses which results in different LS means estimates.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.447</p_value>
            <p_value_desc>Due to the hierarchical testing no adjustment of type I error was necessary.</p_value_desc>
            <method>ANCOVA</method>
            <method_desc>Independent variables in the model were treatment, baseline TWSTRS-Total score, gender, age, pre-treatment of cervical dystonia, and pooled center.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.3</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.1</ci_lower_limit>
            <ci_upper_limit>4.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All SAEs/AEs during Double-Blind Period after Injection, i.e. up to 8-20 weeks after Main Period injection.</time_frame>
      <desc>The table of &quot;Other Adverse Events&quot; includes all non-serious AEs. Only results and AEs of the Double-Blind Period are given as the Extension Period was not placebo-controlled. The investigator asked the patient for AEs systematically at each visit.</desc>
      <group_list>
        <group group_id="E1">
          <title>incobotulinumtoxinA (Xeomin) (240 Units)</title>
          <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;)(active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 240 units; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="E2">
          <title>incobotulinumtoxinA (Xeomin) (120 Units)</title>
          <description>incobotulinumtoxinA (Xeomin, also known as &quot;NT 201&quot; or &quot;Botulinum toxin type A (150 kD), free from complexing proteins&quot;) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, 120 units; Mode of administration: intramuscular injection</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection Dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl; Mode of administration: intramuscular injection</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="81"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="78"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (9.1)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="81"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="78"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="17" subjects_affected="15" subjects_at_risk="81"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="78"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="78"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="81"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="78"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="81"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="78"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Musculosceletal pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="81"/>
                <counts group_id="E2" events="8" subjects_affected="6" subjects_at_risk="78"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="74"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="81"/>
                <counts group_id="E2" events="7" subjects_affected="4" subjects_at_risk="78"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="74"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>No results to be published without written agreement by sponsor; manuscripts to be sent to sponsor at least 6 weeks before submission. Sponsor to give written opinion within 30 days. Sponsor is entitled to exert influence on the contents of publications, to postpone publications up to 36 months after end of the study, and to name co-authors. In case of justified doubts of sponsor, the INVESTIGATOR will consider these doubts in the publication as long as the scientific neutrality is not affected.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angelika Hanschmann</name_or_title>
      <organization>Merz Pharmaceuticals GmbH</organization>
      <phone>++49-69-1503 ext 538</phone>
      <email>angelika.hanschmann@merz.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

